What's Happening?
Pattern Bioscience has announced a significant milestone in its multi-center U.S. clinical trial for the Pattern Pneumonia ID/AST Panel, having enrolled over 1,000 samples. This trial is pivotal for supporting a 510(k) regulatory submission for the company's
first commercial test, which targets critically ill patients with suspected pneumonia. The innovative diagnostic tool aims to provide rapid pathogen identification and antimicrobial susceptibility results, significantly reducing the current two to four-day wait time associated with conventional methods. The trial, which is expected to enroll approximately 2,000 samples, is being conducted across 11 clinical sites. The Pneumonia ID/AST Panel has received Breakthrough Device Designation from the U.S. Food and Drug Administration and is supported by a contract from the Biomedical Advanced Research and Development Authority (BARDA).
Why It's Important?
The development of the Pattern Pneumonia ID/AST Panel is crucial as pneumonia is a leading cause of sepsis, with high mortality rates. The current delay in obtaining pathogen identification and susceptibility results can lead to prolonged ICU stays and increased mortality. By providing rapid results, Pattern Bioscience's technology could significantly improve patient outcomes and reduce the spread of antimicrobial resistance. The successful implementation of this diagnostic tool could transform the management of pneumonia in critically ill patients, offering a faster and more effective approach to treatment.
What's Next?
Pattern Bioscience plans to complete the enrollment of its clinical trial by mid-year and aims to submit its data package to the FDA in the third quarter. If approved, the Pneumonia ID/AST Panel would become the first culture-free, rapid phenotypic susceptibility testing panel available in the U.S. This could lead to broader adoption of rapid diagnostic technologies in healthcare, potentially setting a new standard for the treatment of bacterial infections.
